Find policies, billing codes, payers, states, and providers
HCPCS J9020: Injection, Asparaginase, 10,000 Units
HCPCS Level II code J9020 describes an injection of asparaginase, billed per 10,000 units. Asparaginase is a core antineoplastic agent used in treatment protocols for acute leukemias; accurate coding for drug units and administration supports appropriate clinical documentation and payer adjudication nationwide. This code is relevant across hospital outpatient infusion centers and oncology clinics where parenteral chemotherapy is delivered.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for asparaginase administration, common associated billing elements, and related HCPCS codes for comparison. The publication outlines typical sites of service, common clinical indications tied to leukemia diagnoses, and adjacent codes that may appear on the same service line.
The content provides national-level benchmarks and coding guidance context (billing unit definition and related drug codes), highlights payer coverage inclusion, and summarizes common service-line considerations for oncology infusion services. Data not available in the input is noted where applicable; the focus remains on clear description of the code, its clinical use, and the billing context decision-makers and coding staff need to recognize when J9020 appears on a claim.
Customize your policy alerts
Sign up for hcpcs J9020 policy alerts
Get alerted when payer policies referencing J9020 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J9020 denotes an injection of asparaginase, reported as 10,000 units per billing unit. The service represents administration of an antineoplastic enzyme used primarily in leukemia treatment regimens.
Service type: Medication administration (injectable chemotherapy/antineoplastic)
Typical site of service: Hospital outpatient infusion center or clinic; oncology infusion suite
National Reimbursement Benchmarks
National commercial rates for J9020 cluster around BUCA’s average commercial benchmark of $61.8, with notable variation among major insurers. Blue Cross Blue Shield centers near its own high mean of $62.0 and a median of $65.8, while Cigna and UnitedHealth Group sit well above BUCA’s average with means of $76.4 and $83.4 respectively; Cigna’s median is $77.9 and UnitedHealth Group’s median is $77.5. Aetna is materially lower, with a mean of $25.0 and a median of $12.4, indicating a distinct lower-cost segment in the market.
Dispersion measured by the interquartile range (P75 minus P25) is tightest for Blue Cross Blue Shield at $12.2 (P75 $67.9 minus P25 $56.7) and for Cigna at $16.3 (P75 $84.3 minus P25 $67.0). The widest spread appears with UnitedHealth Group at $10.9 (P75 $81.9 minus P25 $73.1) and BUCA shows a spread of $15.9 (P75 $69.1 minus P25 $53.1). Aetna’s spread is $36.4 (P75 $44.9 minus P25 $8.6), the most pronounced variability among the listed payers.